Avinger to Present at the 8th Annual LD Micro Invitational
May 29, 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., May 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be...
Avinger Receives FDA Clearance of Next Generation Pantheris Device
May 23, 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company...
Avinger Announces First Quarter 2018 Financial Results
May 14, 2018 16:15 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the...
Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
May 04, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will...
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
April 30, 2018 08:30 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that its next...
Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
March 29, 2018 09:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Arne...
Avinger Enters into Settlement Agreement for All Outstanding Securities Class Action Litigation
March 21, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
Avinger Announces Fourth Quarter and Full Year 2017 Results
March 19, 2018 16:01 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD),...
Avinger Provides Update on U.S. Intellectual Property Portfolio
March 13, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced three recent...
Avinger to Announce Fourth Quarter 2017 and Full Year 2017 Results on March 19th, 2018
March 06, 2018 08:00 ET
|
Avinger, Inc.
REDWOOD CITY, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will...